Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.

Eur J Haematol · 2012 · PMC3492844 · PMID 22404182

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Response evaluation At least PR was achieved in 55% of the patients treated with Thal-Dex and in 63% of the patients treated with Bort-Dex, a difference that did not reach statistical significance ( Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.